Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

NYU Langone Health: Clinical Trials & FDA Approval Profile

NYU Langone Health (Global / Institutional) sponsors 86 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 38 active protocols (23 recruiting now), 31 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)19.8%
Median Closed Enrollment vs National (145 pts)31 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for NYU Langone Health
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)86
Active Pipeline (Recruiting Now)38 (23)
Completed vs Stopped Early31 / 17 (19.8%)
Median Closed Actual Enrollment31 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With NYU Langone Health
Hospital Research SiteLocationShared Protocols
NYU Langone Health and Perlmutter Cancer CenterNew York, NY81
Columbia University Irving Medical CenterNew York, NY5
Huntsman Cancer Institute at University of UtahSalt Lake City, UT3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by NYU Langone Health
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05799378Effects of Stopping Hydroxychloroquine in Elderly Lupus DiseasePhase IIIRECRUITING
NCT04474223Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)Phase IIIACTIVE NOT RECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for NYU Langone Health across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the NYU Langone Health Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI